Pharmaceutical Business review

APO grants new patent for Ambrotose AO product: Mannatech

With this, Mannatech will now hold 12 patents for technology related to Ambrotose AO in Australia, Mexico, New Zealand, Singapore, South Africa and South Korea.

Mannatech co-CEO and chief science officer Robert Sinnott said Ambrotose AO technology has been granted patents consistently from governing bodies around the world; thus, validating the diligence and scientific research the company puts behind this important product for health and wellness.

Mannatech holds 63 patents in 30 countries for its health-related technologies.